The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

"Casgevy offers an effective cure for transfusion-dependent beta thalassaemia for people without a stem cell donor," she added, whilst pointing out there is also a desperate need for new options ...

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and transfusion-dependent beta-thalassemia. Sure, it only generated revenue of $8 million in the ...

CRISPR Therapeutics is the gene-editing specialist that created Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Prosper Junior Bakiny (Eli Lilly): What's considered excellent revenue growth depends on the industry. For pharmaceutical companies, especially those with a market cap above $50 billion, year-over ...

Along with partner Vertex Pharmaceuticals, it has won regulatory approval for Casgevy, a revolutionary treatment for SCD and beta-thalassemia. Meanwhile, Intellia is partnered with Regeneron ...